betaxolol has been researched along with Ocular Hypotension in 6 studies
Ocular Hypotension: Abnormally low intraocular pressure often related to chronic inflammation (uveitis).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To observe the efficacy of combined use of brimonidine and betaxolol in treatment of primary open angle glaucoma (POAG) and ocular hypertension." | 9.17 | Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension. ( Chi, W; Li, A; Wang, S; Zhu, X, 2013) |
| "To observe the efficacy of combined use of brimonidine and betaxolol in treatment of primary open angle glaucoma (POAG) and ocular hypertension." | 5.17 | Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension. ( Chi, W; Li, A; Wang, S; Zhu, X, 2013) |
| "This study evaluated systemic and ocular acute safety and intraocular pressure (IOP)-lowering efficacy of travoprost 0." | 5.11 | The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol. ( Asagidag, A; Celik, A; Ermis, SS; Inan, UU; Onrat, E; Orman, A; Ozturk, F; Yucel, A, 2004) |
| "Betaxolol appears to be an effective and well tolerated ocular hypotensive agent in a typical glaucoma population, which includes many patients with cardiopulmonary disease." | 2.68 | Betaxolol eye drops. A clinical trial of safety and efficacy. ( Goldberg, H; Goldberg, I, 1995) |
| "Intraocular pressure was measured using applanation tonometry." | 2.67 | Correlates of acute exercise-induced ocular hypotension. ( Harris, A; Malinovsky, V; Martin, B, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Messina Baas, O | 1 |
| Pacheco Cuellar, G | 1 |
| Toral-López, J | 1 |
| Lara Huerta, SF | 1 |
| Gonzalez-Huerta, LM | 1 |
| Urueta-Cuellar, H | 1 |
| Rivera-Vega, MR | 1 |
| Babayan-Mena, I | 1 |
| Cuevas-Covarrubias, SA | 1 |
| Chi, W | 1 |
| Li, A | 1 |
| Wang, S | 1 |
| Zhu, X | 1 |
| Inan, UU | 1 |
| Ermis, SS | 1 |
| Orman, A | 1 |
| Onrat, E | 1 |
| Yucel, A | 1 |
| Ozturk, F | 1 |
| Asagidag, A | 1 |
| Celik, A | 1 |
| Goldberg, I | 1 |
| Goldberg, H | 1 |
| Nordlund, JR | 1 |
| Pasquale, LR | 1 |
| Robin, AL | 1 |
| Rudikoff, MT | 1 |
| Ordman, J | 1 |
| Chen, KS | 1 |
| Walt, J | 1 |
| Harris, A | 1 |
| Malinovsky, V | 1 |
| Martin, B | 1 |
5 trials available for betaxolol and Ocular Hypotension
| Article | Year |
|---|---|
Efficacy of combined administration of 0.2% brimonidine and 0.5% betaxolol in treatment of primary open angle glaucoma and ocular hypertension.
Topics: Aged; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Drug Administration Schedule; Drug C | 2013 |
The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol.
Topics: Administration, Topical; Adult; Amides; Betaxolol; Bimatoprost; Brimonidine Tartrate; Cardiovascular | 2004 |
Betaxolol eye drops. A clinical trial of safety and efficacy.
Topics: Aged; Aged, 80 and over; Betaxolol; Cardiovascular Diseases; Drug Tolerance; Female; Glaucoma, Open- | 1995 |
The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine.
Topics: Adrenergic alpha-Agonists; Adult; Betaxolol; Brimonidine Tartrate; Cross-Over Studies; Double-Blind | 1995 |
Correlates of acute exercise-induced ocular hypotension.
Topics: Betaxolol; Blood Pressure; Exercise; Female; Heart Rate; Humans; Intraocular Pressure; Lactates; Lac | 1994 |
1 other study available for betaxolol and Ocular Hypotension
| Article | Year |
|---|---|
ADRB1 and ADBR2 gene polymorphisms and the ocular hypotensive response to topical betaxolol in healthy Mexican subjects.
Topics: Administration, Topical; Adrenergic beta-1 Receptor Antagonists; Adult; Antihypertensive Agents; Bet | 2014 |